Literature DB >> 15122701

A novel presenilin 1 mutation associated with Pick's disease but not beta-amyloid plaques.

Bart Dermaut1, Samir Kumar-Singh, Sebastian Engelborghs, Jessie Theuns, Rosa Rademakers, Jos Saerens, Barbara A Pickut, Karin Peeters, Marleen van den Broeck, Krist'l Vennekens, Stephen Claes, Marc Cruts, Patrick Cras, Jean-Jacques Martin, Christine Van Broeckhoven, Peter Paul De Deyn.   

Abstract

Familial forms of frontotemporal dementia (FTD) with tauopathy are mostly caused by mutations in the gene encoding the microtubule-associated protein tau (MAPT). However, rare forms of familial tauopathy without MAPT mutations have been reported, suggesting other tauopathy-related genetic defects. Interestingly, two presenilin 1 (PS1) mutations (Leu113Pro and insArg352) recently have been associated with familial FTD albeit without neuropathological confirmation. We report here a novel PS1 mutation in a patient with Pick-type tauopathy in the absence of extracellular beta-amyloid deposits. The mutation is predicted to substitute Gly-->Val at codon position 183 (Gly183Val) and to affect the splice signal at the junction of the sixth exon and intron. Further clinical-genetic investigation showed a positive family history of FTD-like dementia and suggested that Gly183Val is associated with a phenotypically heterogeneous neurodegenerative disorder. Our results suggest PS1 as a candidate gene for Pick-type tauopathy without MAPT mutations.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15122701     DOI: 10.1002/ana.20083

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  47 in total

Review 1.  Transgenic mouse models of Alzheimer disease: developing a better model as a tool for therapeutic interventions.

Authors:  Masashi Kitazawa; Rodrigo Medeiros; Frank M Laferla
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

Review 2.  The role of cerebral amyloid beta accumulation in common forms of Alzheimer disease.

Authors:  Sam Gandy
Journal:  J Clin Invest       Date:  2005-05       Impact factor: 14.808

Review 3.  Genetics, transcriptomics, and proteomics of Alzheimer's disease.

Authors:  Andreas Papassotiropoulos; Michael Fountoulakis; Travis Dunckley; Dietrich A Stephan; Eric M Reiman
Journal:  J Clin Psychiatry       Date:  2006-04       Impact factor: 4.384

Review 4.  Frontotemporal dementia.

Authors:  Erik D Roberson
Journal:  Curr Neurol Neurosci Rep       Date:  2006-11       Impact factor: 5.081

5.  The future of genetic research on neurodegeneration.

Authors:  Christine Van Broeckhoven
Journal:  Nat Med       Date:  2010-09-21       Impact factor: 53.440

6.  Subjects harboring presenilin familial Alzheimer's disease mutations exhibit diverse white matter biochemistry alterations.

Authors:  Alex E Roher; Chera L Maarouf; Michael Malek-Ahmadi; Jeffrey Wilson; Tyler A Kokjohn; Ian D Daugs; Charisse M Whiteside; Walter M Kalback; Mimi P Macias; Sandra A Jacobson; Marwan N Sabbagh; Bernardino Ghetti; Thomas G Beach
Journal:  Am J Neurodegener Dis       Date:  2013-09-18

Review 7.  Alzheimer's disease as homeostatic responses to age-related myelin breakdown.

Authors:  George Bartzokis
Journal:  Neurobiol Aging       Date:  2009-09-22       Impact factor: 4.673

8.  Presenilin/gamma-Secretase and Inflammation.

Authors:  Carlos A Saura
Journal:  Front Aging Neurosci       Date:  2010-05-18       Impact factor: 5.750

9.  Familial dementia with frontotemporal features associated with M146V presenilin-1 mutation.

Authors:  Miguel A Riudavets; Leonardo Bartoloni; Juan C Troncoso; Olga Pletnikova; Peter St George-Hyslop; Marcelo Schultz; Gustavo Sevlever; Ricardo F Allegri
Journal:  Brain Pathol       Date:  2013-04-25       Impact factor: 6.508

10.  Intracellular calcium deficits in Drosophila cholinergic neurons expressing wild type or FAD-mutant presenilin.

Authors:  Kinga Michno; David Knight; Jorge M Campusano; Jorge M Campussano; Diana van de Hoef; Gabrielle L Boulianne
Journal:  PLoS One       Date:  2009-09-04       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.